Molecular insight into cellulose degradation by the phototrophic green alga Scenedesmus.

Lignocellulose is the most abundant natural biopolymer on earth and a potential raw material for the production of fuels and chemicals. However, only some organisms such as bacteria and fungi produce enzymes that metabolize this polymer. In this work we have demonstrated the presence of cellulolytic activity in the supernatant of Scenedesmus quadricauda cultures and we identified the presence of extracellular cellulases in the genome of five Scenedesmus species.

CBM20CP, a novel functional protein of starch metabolism in green algae.

Ostreococcus tauri is a picoalga that contains a small and compact genome, which resembles that of higher plants in the multiplicity of enzymes involved in starch synthesis (ADP-glucose pyrophosphorylase, ADPGlc PPase; granule bound starch synthase, GBSS; starch synthases, SSI, SSII, SSIII; and starch branching enzyme, SBE, between others), except starch synthase IV (SSIV). Although its genome is fully sequenced, there are still many genes and proteins to which no function was assigned. Here, we identify the OT_ostta06g01880 gene that encodes CBM20CP, a plastidial protein which contains a central carbohydrate binding domain of the CBM20 family, and a coiled coil domain at the C-terminus that lacks catalytic activity.

Starch Synthesis in : The Starch-Binding Domains of Starch Synthase III-B Are Essential for Catalytic Activity.

Starch is the major energy storage carbohydrate in photosynthetic eukaryotes. Several enzymes are involved in building highly organized semi-crystalline starch granules, including starch-synthase III (SSIII), which is widely conserved in photosynthetic organisms. This enzyme catalyzes the extension of the α-1,4 glucan chain and plays a regulatory role in the synthesis of starch.

Reported medication errors in obstetric inpatients in 1 hospital.

Objective: To describe reported medication errors in the obstetric inpatients in 1 hospital.

Study Design: We analyzed all errors, reported voluntarily in a nonpunitive manner, from December 1996 to November 2001.

Results: The 164 medication errors led to 154 class 1 (no harm), 10 class 2 (additional therapy but no additional harm) and 0 class 3 (permanent harm) adverse drug events.